GET DAILY SIGNALSArcadia Biosciences (RKDA) Prepares for Q3 2026 Earnings: Zola Sales Momentum in View
Key Takeaways
- Arcadia Biosciences is expected to report third-quarter 2026 results in early November 2026, with consensus revenue near $2.4 million.
- Analysts expect a loss of roughly $0.46 per share, a narrower deficit than the prior quarter's reported loss.
- The prior quarter was weak: second-quarter 2026 revenue of $1.44 million missed the $1.9 million estimate, while EPS came in at a loss of $2.09.
- Zola coconut water remains the central growth story, with July 2026 sales topping $740,000 as management described an "inflection point."
- Investors will watch gross margin, operating cash burn, and progress on new product launches, including a 1-liter espresso planned for late 2026.
- The company ended the second quarter with $4.2 million in cash after a $4 million private placement closed in June 2026.
Why This Report Carries Extra Weight
Arcadia Biosciences has shifted from its agricultural-biotech roots to focus on wellness products, where the Zola coconut water brand now anchors the business. For a micro-cap with constrained cash resources, each quarterly update offers a clear window into whether Zola can scale while maintaining profitability. The second quarter of 2026 highlighted both advances and hurdles: operating cash burn tightened to $319,000, yet revenue came in below expectations amid inventory shortages and shipping delays. The upcoming third-quarter release will show whether those supply-chain fixes held and if the July sales pickup carried through into steadier, higher-quality results.
What the Numbers Are Expected to Show
Consensus estimates for the third quarter of 2026, ending September 30, 2026, call for revenue around $2.4 million and a loss of about $0.46 per share. That revenue figure sits well above the $1.44 million posted in the second quarter, based on hopes that improved distribution and supply-chain fixes will support stronger Zola sales. The projected loss also narrows from the prior quarter's $2.09 per share, though historical per-share results have swung due to non-cash items like valuation adjustments. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Arcadia has missed consensus revenue in recent periods, with the second quarter falling roughly 24% short and the first quarter of 2026 also below projections. Attention will likely center on revenue trends, gross margins—which have stayed above 30% for more than a decade—and cash usage rather than the headline EPS figure alone.
How the Market Is Approaching the Release
Sentiment ahead of the report remains measured. The share price trades near historic lows, and the stock has reacted sharply to past earnings surprises, often with GAAP losses exceeding forecasts. The second-quarter results included a revenue shortfall paired with a wider loss, which can weigh on a thinly traded micro-cap. Management’s notes on July sales above $740,000 and a $1 million year-over-year drop in SG&A expenses provide a counterbalance, yet risks around Zola supply execution, retail expansion pace, and cash preservation stay front of mind.
What to Watch Beyond the Print
Looking ahead, several themes stand out. The first is whether Zola’s revenue gains can hold. Management has highlighted an “inflection point” and re-acceleration in monthly sales, but confirmation that this reflects more than a restocking rebound after earlier delays will matter. Product development comes next: a 1-liter espresso version is slated for the fourth quarter of 2026 with commitments from the two largest customers, alongside three further launches planned for the first half of 2027. These moves could broaden revenue and strengthen shelf presence.
The financial base is another focus. With $4.2 million in cash at the end of June 2026 following the private placement, the company sees a route to support growth, though gross margin patterns and operating cash flow will stay key, as further raises could dilute shareholders. Distribution progress and inventory updates, which affected the prior two quarters, also warrant tracking. The overall picture on these elements, beyond any single EPS outcome, should shape views on the company’s progress.
Using AI Tools in My Research Process
When reviewing names like this, I often turn to Tickeron’s AI Screener to quickly surface comparable micro-cap opportunities and pattern-based signals. It helps filter across technical and fundamental criteria without manual effort, which keeps the analysis efficient while I focus on the core business drivers.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
RKDA's RSI Indicator ascends from oversold territory
The RSI Indicator for RKDA moved out of oversold territory on November 05, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 42 similar instances when the indicator left oversold territory. In 38 of the 42 cases the stock moved higher. This puts the odds of a move higher at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 57 of 68 cases where RKDA's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 84%.
The Momentum Indicator moved above the 0 level on November 02, 2026. You may want to consider a long position or call options on RKDA as a result. In 65 of 84 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 77%.
The Moving Average Convergence Divergence (MACD) for RKDA just turned positive on October 23, 2026. Looking at past instances where RKDA's MACD turned positive, the stock continued to rise in 37 of 40 cases over the following month. The odds of a continued upward trend are 90%.
Following a +7.68% 3-day Advance, the price is estimated to grow further. Considering data from situations where RKDA advanced for three days, in 176 of 225 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
RKDA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where RKDA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for RKDA entered a downward trend on October 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 6 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 32 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.635) is normal, around the industry mean (6.720). P/E Ratio (-0.037) is within average values for comparable stocks, (7.191). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (8.458). Dividend Yield (0.000) settles around the average of (0.050) among similar stocks. P/S Ratio (0.189) is also within normal values, averaging (5.003).
The Tickeron Seasonality Score of 46 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 96 (best 1 - 100 worst), indicating slightly worse than average price growth. RKDA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RKDA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of agriculture based technologies
Industry FoodMajorDiversified
Advertisement